Get the Daily Brief
Latest Biotech News
BioMarin buys Amicus for $4.8B: gains Fabry and Pompe drugs
BioMarin agreed to acquire Amicus Therapeutics in an all‑cash deal valued at about $4.8 billion, securing two marketed rare‑disease products for Fabry and Pompe diseases and U.S. rights to a phase...
FDA clears Cytokinetics’ heart drug — company wins first U.S. approval
The U.S. Food and Drug Administration approved Cytokinetics’ new therapy Myqorzo for obstructive hypertrophic cardiomyopathy, marking the biotech’s first U.S. drug approval. Company disclosures...
ADC program...FDA pauses Daiichi‑Merck Phase 3 after deaths
Regulators and sponsors paused enrollment in the Phase 3 IDeate‑Lung02 study of the antibody‑drug conjugate ifinatamab deruxtecan after a higher‑than‑anticipated incidence of grade‑5 interstitial...
Takeda’s TYK2 pill succeeds in Phase 3 — filings planned for 2026
Takeda reported that zasocitinib, its TYK2 inhibitor acquired in a multibillion‑dollar deal, met co‑primary and key secondary endpoints in two Phase 3 trials for plaque psoriasis. The company said...
Lilly’s oral GLP‑1 maintains weight loss — Phase 3 meets endpoints
Eli Lilly reported positive top‑line results from the Phase 3 Attain‑Maintain trial of orforglipron, an oral GLP‑1 receptor agonist, showing superior weight maintenance over 52 weeks versus...
Moderna gets CEPI backing: $54M to advance H5 pandemic vaccine
Moderna secured up to $54.3 million from the Coalition for Epidemic Preparedness Innovations (CEPI) to advance its H5 avian influenza mRNA vaccine mRNA‑1018 into Phase 3 testing. The grant follows...
JAX and NYSCF unite: nonprofit research engine launched in NYC
The Jackson Laboratory completed its acquisition of the New York Stem Cell Foundation and held a launch event at NYSCF’s Manhattan facilities to mark the formation of a unified nonprofit research...
Epigenovo commercializes scFFPE‑ATAC: startup seeks funding after paper
Swedish spinout Epigenovo disclosed proof‑of‑concept for a high‑throughput single‑cell chromatin accessibility assay compatible with formalin‑fixed paraffin‑embedded (FFPE) tissues — scFFPE‑ATAC —...
Parse and Codebreaker map variant effects at single‑cell scale
Parse Biosciences and Codebreaker Labs announced a collaboration to combine engineered variant libraries with Parse’s single‑cell transcriptomics to experimentally measure how genetic variants...
Galux and Boehringer ink AI protein‑design pact — purposeful molecules
South Korean AI‑driven protein discovery company Galux signed a research collaboration with Boehringer Ingelheim to evaluate AI‑enabled design of purpose‑specific protein molecules. The initial...
Patient deaths trigger partial hold: Daiichi, Merck pause global Phase III ADC
The Phase III global program testing an antibody‑drug conjugate (I‑Dxd/ifinatamab deruxtecan) has been placed on partial hold after a higher‑than‑anticipated number of fatal interstitial lung...
BioMarin buys Amicus for $4.8B: rare disease portfolio expands
BioMarin agreed to acquire Amicus Therapeutics in an all‑cash transaction valued at about $4.8 billion, adding two marketed therapies for Pompe and Fabry diseases and U.S. rights to a late‑stage...
Cytokinetics wins FDA nod: Myqorzo approved for obstructive HCM
The FDA granted approval to Cytokinetics' Myqorzo—the company’s first U.S. drug—for obstructive hypertrophic cardiomyopathy, marking a milestone after a nearly three‑decade effort. Cytokinetics...
Takeda’s TYK2 drug clears Phase 3: zasocitinib posts dual trial wins
Takeda reported that zasocitinib achieved primary and key secondary endpoints in two Phase III trials for plaque psoriasis, with more than half of patients reaching 'clear or almost clear' skin...
Lilly’s oral GLP‑1 maintains weight: orforglipron meets Phase 3 goals
Eli Lilly said orforglipron, a once‑daily oral GLP‑1 receptor agonist, met primary and key secondary endpoints in a Phase 3 maintenance trial that tested whether the pill preserves weight loss...
Moderna secures CEPI funding: H5 pandemic flu vaccine advances to Phase 3
Moderna secured up to $54.3 million from CEPI to advance its mRNA H5 pandemic influenza candidate (mRNA‑1018) into Phase 3 testing and committed to allocating 20% of production capacity for low‑...
vConTACT3 and ML scale virus taxonomy: machine learning remaps viral classification
Researchers introduced vConTACT3, a machine‑learning framework enabling scalable, hierarchical classification of viruses across eukaryotic and prokaryotic domains, and published methods in Nature...
Epigenovo commercializes single‑cell FFPE ATAC: scFFPE‑ATAC heads to market
Swedish startup Epigenovo is commercializing scFFPE‑ATAC, a high‑throughput single‑cell chromatin accessibility assay compatible with formalin‑fixed paraffin‑embedded (FFPE) tissues. The Uppsala...
Parse teams with Codebreaker: single‑cell variant effect mapping
Parse Biosciences and Codebreaker Labs announced a collaboration to experimentally map how engineered genetic variants alter single‑cell transcriptomes, combining Codebreaker’s variant libraries...
Insmed’s momentum stalls: Brinsupri fails nasal inflammation study, market hit
Insmed disclosed that Brinsupri (brensocatib) failed a Phase 2b trial in chronic rhinosinusitis without nasal polyps, ending a run of positive results that had elevated the company’s valuation....